Pioneers of The World’s First TCR Therapy

Apr. 24, 2024 • Time: 10:00 AM EDT

Immunocore announces upcoming presentation and posters at ASCO 2024

Apr. 4, 2024 • Time: 4:00 PM EDT

Immunocore to present at upcoming investor conferences

Mar. 5, 2024 • Time: 4:30 PM EST

Immunocore presented two posters at CROI 2024

Mar. 1, 2024 • Time: 7:00 AM EST

Immunocore to present at upcoming investor conferences

Feb. 28, 2024 • Time: 7:34 AM EST

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Feb. 22, 2024 • Time: 7:00 AM EST

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Feb. 21, 2024 • Time: 7:00 AM EST

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Jan. 30, 2024 • Time: 11:30 PM EST

Immunocore Prices Upsized Convertible Senior Notes Offering

Jan. 29, 2024 • Time: 4:05 PM EST

Immunocore Announces Proposed Convertible Senior Notes Offering

Jan. 5, 2024 • Time: 7:00 AM EST

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation